Peptides›Blend, Healing›BPC-157 + TB-500 (Wolverine Blend)

BPC-157 + TB-500 (Wolverine Blend)

/ Multi-component research-peptide blend

TIER 3 · PreclinicalN = 0 · TESTING PENDING

ALIAS · Wolverine Blend · TB/BP Blend · BPC-157/TB-500 stack · Healing peptide stack

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequenceTwo-component blend: BPC-157 (15-residue pentadecapeptide) + TB-500 (17-residue C-terminal fragment of thymosin-β4)

MW · —CLASS · Multi-component research-peptide blendCATEGORY · Blend, Healing

Tier 3 by component evidence. Each component independently has rodent and in-vitro literature on tissue repair (BPC-157 single-lab dominant from Sikiric group; TB-4 broader literature plus a failed Phase 3 trial of the parent molecule). The BLEND itself has no published clinical or preclinical study — its tier rating is inherited from the weaker of the two components.

§ B · Mechanism of action

This page is editorial coverage of a vendor-marketed blend, not of a single chemical entity. The proposed rationale for combining BPC-157 (gastric pentadecapeptide, hypothesised tissue-repair effects in tendon/ligament/GI models) with TB-500 (actin-sequestering thymosin-β4 fragment, hypothesised soft-tissue repair effects) is convergent action on tissue repair through different mechanisms — angiogenesis, growth-factor expression, and cytoskeletal remodelling.

There is no published primary literature on the COMBINATION pharmacokinetics, additivity, antagonism, or clinical effect. Reading is by inference from each component's individual evidence base.

§ C · Human clinical evidence

None for the combination. Component evidence: BPC-157 has no human RCT data; TB-4 (the parent of TB-500) had a Phase 3 corneal trial of RGN-259 that failed its primary endpoint. Vendor blend marketing for tendon, ligament, or surgical recovery indications has no controlled clinical support.

§ D · Primary literature

PubMed21548867Sikiric P et al. — Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design · reviewTwenty-year review of BPC-157 preclinical literature, predominantly from one investigator group: GI ulcer healing, tendon and ligament repair, NSAID protection, dopaminergic effects.Limitations: Single-lab dominance — vast majority of cited primary studies authored by Sikiric's group at University of Zagreb; no Western replication of central findings; no human RCT data.2011

PubMed16099219Goldstein AL et al. — Thymosin β4: actin-sequestering protein moonlights to repair injured tissues · Trends in Molecular Medicine · reviewFoundational review of TB-4's tissue-repair mechanisms beyond G-actin sequestration: angiogenesis, anti-inflammatory cytokine modulation, stem-cell recruitment in dermal and corneal models.Limitations: Review by inventors of the molecule; written before the failed Phase 3 corneal trial of RGN-259.2005

§ F · Safety signal

No combined safety data. Component safety: BPC-157 has no formal Phase 1 human safety study; TB-500 / TB-4 safety data come primarily from the corneal trials and small rodent studies. The combination has no peer-reviewed safety database.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Single-lab dominance affects the BPC-157 component: most cited primary studies originate from Predrag Sikiric's group at the University of Zagreb. Independent Western replication of the central tendon/ligament repair findings is largely absent. This is a load-bearing limitation when interpreting any blend that includes BPC-157.

The 'Wolverine' branding is vendor marketing, not a recognised clinical or scientific term. There is no standardised dose ratio between components across vendors; what one supplier calls 'Wolverine' is not interchangeable with another supplier's product of the same name.